133 related articles for article (PubMed ID: 25354264)
1. Comments on 'Generalized erythroderma and palmoplantar hyperkeratosis in a patient receiving TNF-alpha antagonist therapy'.
Martinez-Escala ME; Guitart J
J Cutan Pathol; 2015 Apr; 42(4):295-6. PubMed ID: 25354264
[No Abstract] [Full Text] [Related]
2. Generalized erythroderma and palmoplantar hyperkeratosis in a patient receiving TNF-alpha antagonist therapy.
Dunst-Huemer KM; Scheurecker C; Auboeck J
J Cutan Pathol; 2013 Sep; 40(9):855-6. PubMed ID: 23808653
[No Abstract] [Full Text] [Related]
3. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
[TBL] [Abstract][Full Text] [Related]
4. Psoriasiform reactions to anti-tumor necrosis factor α therapy.
Nguyen K; Vleugels RA; Velez NF; Merola JF; Qureshi AA
J Clin Rheumatol; 2013 Oct; 19(7):377-81. PubMed ID: 24048106
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous lupus erythematosus induced by the treatment with tumor necrosis factor antagonists.
Sifuentes Giraldo WA; Ahijón Lana M; Vázquez Díaz M
Reumatol Clin; 2013; 9(4):255-6. PubMed ID: 23608052
[No Abstract] [Full Text] [Related]
6. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab.
Tammaro A; Persechino S; Abruzzese C; Narcisi A; Cortesi G; Parisella FR; Laganà B
Int J Immunopathol Pharmacol; 2012; 25(2):499-501. PubMed ID: 22697082
[TBL] [Abstract][Full Text] [Related]
7. Skin lesions and treatment with tumor necrosis factor alpha antagonists.
Hernández MV; Meineri M; Sanmartí R
Reumatol Clin; 2013; 9(1):53-61. PubMed ID: 22766431
[TBL] [Abstract][Full Text] [Related]
8. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.
Osório F; Magro F; Lisboa C; Lopes S; Macedo G; Bettencourt H; Azevedo F; Magina S
Dermatology; 2012; 225(2):163-7. PubMed ID: 23052429
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
[No Abstract] [Full Text] [Related]
12. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
Seneschal J; Milpied B; Vergier B; Lepreux S; Schaeverbeke T; Taïeb A
Br J Dermatol; 2009 Nov; 161(5):1081-8. PubMed ID: 19681863
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution.
Gaya DR; Aitken S; Fennell J; Satsangi J; Shand AG
Gut; 2006 Oct; 55(10):1524-5. PubMed ID: 16966709
[No Abstract] [Full Text] [Related]
17. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
18. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
19. Erythroderma in the era of biological therapies.
Zattra E; Belloni Fortina A; Peserico A; Alaibac M
Eur J Dermatol; 2012; 22(2):167-71. PubMed ID: 22321651
[TBL] [Abstract][Full Text] [Related]
20. [Long-term psoriasis treatment].
Jullien D; Battistella M
Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
